BDR Pharmaceuticals Internationals

What BDR Pharmaceuticals Internationals does

BDR Pharmaceuticals Internationals Pvt. Ltd. is a privately held Indian specialty pharmaceutical company headquartered in Mumbai, founded in 2002-2003 by Dharmesh Shah. The company operates across four therapeutic segments — oncology, critical care, gynecology, and neurology — with a focus on making affordable life-saving medications accessible through a multi-branding strategy. BDR maintains a vertically integrated operating model spanning API manufacturing (at subsidiaries BDR Lifesciences and Virdev Intermediates in Gujarat), finished formulations (including a dedicated WHO GMP and EU GMP certified oncology oral facility), and specialty pellets (Magnum Chemi-Gran in Hyderabad). The company is supported by DSIR-accredited R&D centers in Vadodara and Hyderabad with over 40 scientists, and proprietary Novel Drug Delivery System capabilities including liposomal, microsphere, depot, and pegylated delivery technologies.

The company generates revenue through four distinct streams: (1) API manufacturing and sales under cGMP standards with global accreditations (WHO GMP, EU GMP, ANVISA, COFEPRIS, Belarus GMP, PPB-Kenya, THAI MOH); (2) formulation manufacturing and marketing across oral dosage forms; (3) contract manufacturing services to leading Indian pharmaceutical companies including Sun Pharma, Torrent, Zydus, Intas, Emcure, Alkem, Dr Reddy's, Macleods, Abbott, Biocon, and Glenmark; and (4) international technology transfer agreements with overseas partners for emerging markets. BDR holds US Patent 8,841,457 B2 for Etoricoxib, has filed patents for Linezolid, and claims over 140 molecules launched first-in-India with ~30% global market share in Cancidas (caspofungin).

The go-to-market combines direct B2B contract manufacturing, international technology transfer licensing, and a unique multi-branding distribution model that leverages marketing partnerships with major Indian pharma companies for domestic reach while pursuing direct specialty formulation sales in oncology, critical care, gynecology, and neurology. In May 2022, a consortium led by Multiples Alternate Asset Management invested approximately $88 million for a 9.3% stake, implying a company valuation of approximately Rs 7,500 crore (~$920 million), with proceeds earmarked for R&D, manufacturing expansion, and acquisitions.

Name

BDR Pharmaceuticals Internationals

Legal name

BDR Pharmaceuticals Internationals Pvt. Ltd.

Website

https://bdrpharma.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

BDR Pharmaceuticals Internationals is a Mumbai-based, privately held Indian specialty pharmaceutical company founded in 2002-2003 that develops and manufactures niche APIs and formulations in oncology, critical care, gynecology, and neurology for affordable distribution across domestic and emerging markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Generic pharmaceuticals
• API manufacturing
• Oncology medications
• Contract manufacturing
• Novel drug delivery

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. API Manufacturing and Sales: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) including niche APIs in oncology and other specialty segments. The company operates multiple API facilities in Gujarat and Hyderabad with cGMP standards and global accreditations.
2. Formulations Manufacturing and Sales: Manufacturing and marketing of finished formulations including oral dosages, tablets, capsules in various therapeutic segments. State-of-the-art WHO GMP and EU-GMP certified oncology oral formulation facility.
3. Contract Manufacturing Services: High-quality contract manufacturing services provided to leading pharmaceutical companies in India. Modern facilities with sophisticated quality systems and state-of-the-art equipment.
4. Technology Transfer Agreements: International technology transfer agreements with overseas partners allowing commercialization of selected products under confidentiality agreements for emerging markets.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

BDR Pharmaceuticals Internationals develops, manufactures, and markets niche specialty pharmaceutical products in four therapeutic segments: oncology, critical care, gynecology, and neurology. The company manufactures both Active Pharmaceutical Ingredients (APIs) and finished formulations (tablets, capsules, oral dosages, pellets) in DSIR-accredited, WHO GMP and EU GMP certified facilities, and also offers contract manufacturing services to other pharmaceutical companies.

Product overview

BDR Pharmaceuticals Internationals is an Indian pharmaceutical company operating as a niche player in specialty medications. The company manufactures both APIs (Active Pharmaceutical Ingredients) and Finished Formulations in-house, supported by DSIR-accredited R&D facilities. Their product portfolio centers on four therapeutic segments: Oncology, Critical Care, Gynecology, and Neurology. The core offerings include API manufacturing (niche APIs with cGMP standards), Formulations (generic formulation development in various dosage forms), and Pellets (sustained/modified release formulations using innovative drug delivery technologies). The company also offers contract manufacturing services to other pharmaceutical companies. Their unique multi-branding strategy enables distribution of medicines at affordable prices through various partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• API (Active Pharmaceutical Ingredients) Manufacture and sale of niche Active Pharmaceutical Ingredients in oncology and other specialty therapeutic segments, produced in cGMP-compliant facilities with global accreditations. Targeted at pharmaceutical formulation companies and B2B partners.
• Generic Formulations Finished generic pharmaceutical formulations (tablets, capsules, oral dosages) developed and marketed across oncology, critical care, gynecology, and neurology therapeutic segments. Targeted at healthcare distributors, hospitals, and pharmacy chains through the multi-branding strategy.
• Sustained and Modified Release Pellets Pellet-based pharmaceutical products using sustained and modified release drug delivery technologies, focused on niche specialty product development. Targeted at formulation partners requiring advanced drug delivery intermediates.
• Oncology Products Specialized oncology pharmaceutical products including oral formulations and APIs manufactured in dedicated facilities to prevent cross-contamination. Includes first-in-India launches of pegylated liposomal doxorubicin, edaravone injection, caspofungin injection, daptomycin injection, abiraterone tablets, everolimus tablets, and fulvestrant injection.
• Contract Manufacturing Services Contract manufacturing of pharmaceutical products for leading Indian pharmaceutical companies, supported by modern facilities with sophisticated quality systems, cGMP compliance, and state-of-the-art equipment. Targeted at enterprise pharma marketers requiring specialized manufacturing capacity.

Quantifiable outcome

• 50% annual growth rate achieved since inception
• +5 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core.

• Sun Pharma / RanbaxycoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• Torrent PharmacoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• Zydus CadillacoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• Intas PharmacoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• Emcure PharmaceuticalscoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• AlkemcoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• Dr ReddyscoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• Macleods PharmacoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• AbbottcoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• BioconcoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.
• GlenmarkcoreChannel Partner/ Reseller/ DistributorMarketing partnership for formulation business distribution in Indian pharmaceutical market.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Natco Pharma: Indian specialty generic pharma with a strong focus on oncology, complex generics and first-to-market launches, mirroring BDR's niche-molecule and compulsory-license strategy. Both companies compete head-to-head in oncology and complex injectable categories in India and emerging markets.
• Hetero Drugs: Indian vertically integrated API and formulation manufacturer specializing in complex generics including ARVs, oncology and niche molecules; the most direct comparable given the BDR founder's prior leadership at Hetero and similar technology-driven, emerging-market export profile.
• Aurobindo Pharma: Large Indian generic manufacturer with broad API and formulation portfolio including sterile injectables and oncology, providing a benchmark for global export scale, regulatory depth and specialty-segment growth that BDR aspires to.
• Cipla: Major Indian generic pharma with a strong specialty and complex generics franchise, comparable go-to-market through partnerships and direct sales, and an overlapping therapeutic footprint in critical care, oncology and respiratory categories.
• Dr. Reddy's Laboratories: Vertically integrated Indian pharma with API and formulation businesses and a significant channel partnership with BDR; comparable specialty generics pipeline, sterile injectables capability and global regulatory footprint.
• Lupin Limited: Indian specialty generic pharma with a complex generics and biosimilars pipeline and US FDA-approved sterile facilities, representing a relevant comp on technology, regulatory depth and global specialty ambitions.
• Emcure Pharmaceuticals: Indian specialty pharma with strong presence in oncology, gynecology, neurology and critical care, directly overlapping BDR's core therapeutic segments and serving as both a peer and a channel partner.
• Intas Pharmaceuticals: Indian specialty generic manufacturer with a leading oncology and biopharma franchise and global distribution; comparable in therapeutic focus (oncology, neurology) and emerging-market export orientation.

Broad incumbents

• Sun Pharmaceutical Industries: Largest Indian pharma company and a channel partner of BDR; overlaps in specialty generics and global formulations but is significantly larger and more diversified, including specialty branded, OTC and API businesses.
• Biocon Limited: India-based biopharma with biosimilars, complex generics and APIs, comparable in vertical integration and emerging-market reach; a BDR channel partner and relevant peer for the biologics/complex-injectables trajectory BDR is building toward.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/BDRPharma
• Facebookfacebook.com/BdrBaroda
• LinkedInlinkedin.com/company/bdr-pharma/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BDR Pharmaceuticals Internationals